NMR and DFT calculation study on structures of 2-[2-nitro-4-(trifluoromethyl)benzoyl]cyclohexane-1,3-dione (NTBC) and its two metabolites isolated from urine of patients suffering from tyrosinemia type I

Adam Gryff-Keller , Przemysław Szczeciński , Anna Kraska-Dziadecka


2-[2-Nitro-4-(trifluoromethyl)benzoyl]cyclohexane-1,3-dione (NTBC) is an active component of nitisinone, a medicine against tyrosinemia type I. Using 1H, 13C and 19F NMR spectroscopy it has been found that in the urine of patients treated with nitisinone two compounds possessing CF3 group are always present. They have been isolated by using TLC technique and identified as 4-hydroxy-2-[2-nitro-4-(trifluoromethyl)benzoyl]cyclohexane-1,3-dione and 5-hydroxy-2-[2-nitro-4-(trifluoromethyl)benzoyl]cyclohexane-1,3-dione, the latter being previously unknown. The constitution, tautomerism and stereochemistry of these compounds have been thoroughly investigated using 1H and 13C NMR spectroscopy supported by theoretical calculations. Molecular structures have been optimized using density functional theory (DFT) with PBE1PBE functional and 6-31G* basis set. In NMR parameter calculations, the larger 6-311++G(2d,p) basis set has been used. At both calculation stages, the polarizable continuum model of the solvent has been employed. Copyright © 2010 John Wiley \& Sons, Ltd.
Author Adam Gryff-Keller (FC / DOC)
Adam Gryff-Keller,,
- Department Of Organic Chemistry
, Przemysław Szczeciński (FC / DOC)
Przemysław Szczeciński,,
- Department Of Organic Chemistry
, Anna Kraska-Dziadecka
Anna Kraska-Dziadecka,,
Journal seriesJournal of Physical Organic Chemistry, ISSN 1099-1395, (B 0 pkt)
Issue year2011
Keywords in EnglishDFT calculation, metabolism, NMR spectroscopy, NTBC, tautomerism
URL http://onlinelibrary.wiley.com/doi/10.1002/poc.1736/abstract
Score (nominal)0
Citation count*
Share Share

Get link to the record

* presented citation count is obtained through Internet information analysis and it is close to the number calculated by the Publish or Perish system.
Are you sure?